Status:
RECRUITING
Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Neutrophil-mediated Inflammatory Dermatoses
Inflammatory Dermatoses
Eligibility:
All Genders
18-100 years
Brief Summary
This study is to identify rare, disease-causing mutations of several rare neutrophil dermatoses. To identify associations between NMID and variants in the genome next generation sequencing, mainly who...
Detailed Description
The origin of rare severe inflammatory skin diseases in dermatology is insufficiently known. They have in common the presence and activation of phagocytes, affect the quality of life through pain and ...
Eligibility Criteria
Inclusion Criteria:
- written consent of the participating person
- diagnosis of a disease in the NMID form group or proband of the control group
Exclusion Criteria for patients:
- Missing informed consent if samples collected after 2014
- no diagnosis of NMID
Exclusion Criteria for healthy controls:
- Missing informed consent
Key Trial Info
Start Date :
February 3 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2029
Estimated Enrollment :
3370 Patients enrolled
Trial Details
Trial ID
NCT05732987
Start Date
February 3 2023
End Date
September 1 2029
Last Update
August 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Clinic of Dermatology
Basel, Switzerland, 4031